Gestational Trophoblastic Disease (GTD)
Prognosis
This section is being prepared by our editorial process.
🔬 Histological Types
📚 Latest Research
The role of chemotherapy in high-risk gestational trophoblastic neoplasia.
Braga A, et al
A narrative review published in Expert Review of Anticancer Therapy concludes that multiagent chemotherapy remains the cornerstone of treatment for high-risk gestational trophoblastic neoplasia (GTN), yet delays in diagnosis, inadequate risk stratification, and inappropriate chemotherapy regimens continue to be the primary determinants of adverse outcomes in this otherwise highly chemosensitive malignancy. Synthesizing evidence from PubMed/MEDLINE, Scopus, and Web of Science through July 2026, the review covers first-line and salvage chemotherapy strategies, mechanisms of chemoresistance, and management of relapsed disease. The authors conclude that future advances in molecular diagnostics, predictive biomarkers, targeted therapies, and immunotherapy — combined with continued centralization of care — hold the potential to further personalize treatment, reduce toxicity, and ultimately eliminate preventable mortality associated with high-risk GTN.
Expert review of anticancer therapy
Source →Longitudinal AMH trajectories, ovarian reserve recovery, and fertility outcomes after multiagent chemotherapy for high-risk gestational trophoblastic neoplasia: A real-world cohort study.
Xue W, et al
In a real-world cohort of 68 women treated with multiagent chemotherapy for high-risk gestational trophoblastic neoplasia, ovarian reserve — measured by anti-Müllerian hormone (AMH) — dropped profoundly during treatment (median 0.04 ng/mL) but recovered substantially by 6 months (median 1.26 ng/mL), with 73.5% of patients reaching AMH ≥ 1.0 ng/mL. The FAEV regimen (fluorouracil, actinomycin D, etoposide, vincristine) was associated with less acute gonadotoxicity than EMA/CO, showing geometric mean AMH ratios of 2.19 during treatment and 2.55 at 1 month post-chemotherapy, and a higher 6-month recovery rate (86.2% vs. 74.4%). Among 28 uterus-preserving patients who actively attempted pregnancy, 71.4% (20/28) achieved at least one live birth, and a higher 6-month AMH level was associated with live birth (median 1.95 vs. 1.08 ng/mL). Importantly, hysterectomy did not appear to compromise longer-term AMH recovery, and the authors recommend using 6-month AMH to guide individualized fertility counseling.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
Source →Variability in β-human chorionic gonadotropin concentrations following evacuation of a hydatidiform mole pregnancy: A retrospective cohort study from Vietnam.
Tran LT, et al
A retrospective cohort study of 560 Vietnamese women with molar pregnancy found that serum β-hCG levels declined significantly faster in patients who progressed to gestational trophoblastic neoplasia (GTN) than in those with relapsed molar pregnancy (-20,651.22 vs. -11,593 mUI/mL and -46,329.23 vs. -12,946.26 mUI/mL, p < 0.001), establishing the post-evacuation β-hCG regression curve as a clinically meaningful tool to distinguish GTN from hydatidiform mole recurrence. Conducted at Tu Du Hospital, Vietnam between January 2019 and December 2020, the study included 298 patients with complete hydatidiform mole and 262 with partial hydatidiform mole, of whom 97 developed GTN with a median time to diagnosis of 8.75 ± 4.41 (range 4–26) weeks. These findings reinforce the essential role of serial serum β-hCG surveillance following uterine evacuation for early identification of disease progression in molar pregnancy patients.
The Journal of international medical research
Source →💊 Therapies
This section is being prepared by our editorial process.